Iridex Beats Profit Forecasts on Cost Cuts Amidst Revenue Dip

MOUNTAIN VIEW, CA – May 19, 2026 – Iridex Corporation (Nasdaq: IRIX) presented a picture of strategic resilience today, posting first-quarter 2026 financial results that saw the medical technology firm significantly narrow its net loss and surpass analyst profit expectations, even as total revenue experienced a slight decline. The market responded favorably, with the company's stock rising in after-hours trading, suggesting investors are valuing operational discipline in a complex global market.

The ophthalmology device maker reported total revenue of $11.8 million for the quarter ending April 4, 2026, a 1% dip from the $11.9 million recorded in the same period last year and missing the consensus analyst forecast of $13.17 million. However, the bottom-line narrative told a different story. Iridex posted a net loss of just $0.5 million, or $0.03 per share, a dramatic improvement from the $1.7 million net loss, or $0.10 per share, in the prior-year quarter. This performance comfortably beat Wall Street's expectation of a $0.05 per share loss.

Glaucoma Segment Shines as Growth Engine

The standout performer in the company's portfolio was its Cyclo G6® glaucoma product family. Revenue from this segment surged 14% year-over-year, climbing to $3.6 million from $3.2 million. This growth was driven by a notable increase in the sale of disposable Cyclo G6 probes, which rose to 15,500 units from 13,900 in the first quarter of 2025. The steady sale of 24 Cyclo G6 laser systems, matching the prior year's number, combined with the uptick in probe sales, indicates growing adoption and, more importantly, consistent clinical utilization of the company's proprietary MicroPulse® technology for glaucoma treatment.

This performance is particularly significant against the backdrop of a growing global glaucoma treatment market, valued at nearly $7 billion in 2026. An aging global population and the increasing prevalence of the disease are fueling demand for effective treatments. The medical community's growing acceptance of laser-based therapies like Selective Laser Trabeculoplasty (SLT) as a first-line treatment for open-angle glaucoma creates a favorable environment for Iridex's technology, which offers a minimally invasive approach to managing intraocular pressure.

Global Headwinds Buffet Retina Business

In stark contrast to the glaucoma segment's success, the company's retina product line faced significant challenges. Retina product revenue declined to $5.8 million, down from $6.6 million in the prior-year period. Management attributed this downturn to a combination of "international supply constraints and delayed regulatory approvals," a challenge echoing across the broader medical device industry.

While the company noted strength in its U.S. retina sales, the international hurdles were substantial enough to drag down the segment's overall performance. These issues are not unique to Iridex. The global medical technology supply chain has been under pressure from geopolitical conflicts, which can disrupt shipping and component availability. Iridex specifically acknowledged that its full-year guidance accounts for "market disruptions from the conflict in the Middle East." Furthermore, navigating the increasingly fragmented and complex regulatory landscape in key markets like Europe and China has become a significant operational hurdle for many device manufacturers, often leading to costly and unpredictable delays.

A Disciplined Path Toward Profitability

The most compelling aspect of Iridex's first-quarter report was its demonstration of rigorous cost control. The company reduced its operating expenses by 4% to $5.1 million. This reduction was not a result of a single action but a series of deliberate strategic moves, including lower consulting costs, reduced legal expenses related to prior deals, and savings realized from an initiative to transfer general and administrative functions. The company expects these savings to continue, projecting approximately $165,000 in quarterly savings from relocating certain G&A functions out of its high-cost California base, with a planned headquarters relocation later in 2026 expected to cut fixed costs by another $600,000 annually.

This fiscal discipline was the primary driver behind the sharply reduced net loss. However, the company is still grappling with margin pressure. Gross margin for the quarter fell to 40% from 43% a year ago, which the company attributed to higher manufacturing costs and the impact of recent tariffs. To combat this, Iridex is in the midst of a multi-year transition to move production to lower-cost contract manufacturers, a strategic shift intended to improve its cost of goods sold and bolster margins in 2026 and beyond.

Reaffirming Confidence for the Year Ahead

Despite the mixed top-line results and external pressures, Iridex's leadership expressed confidence in their strategy and reaffirmed their full-year 2026 financial guidance. The company continues to project annual revenue between $51 million and $53 million and expects to generate positive operating cash flow for the full fiscal year.

“Looking back at the first quarter of 2026, I am encouraged by our execution across the business as first quarter results were in line with our expectations, building the foundation for a cash flow positive fiscal year,” said Patrick Mercer, President and CEO of Iridex, in the company's press release. “Our U.S. glaucoma business delivered solid growth, and our cost structure improvements are flowing through as planned. We remain confident in our ability to deliver on the priorities we’ve outlined: expanding G6 utilization, advancing regulatory approvals, and continuing to drive gross margin improvement.”

The company's cash position decreased by $1.4 million during the quarter to $4.6 million, but management characterized this as a planned and seasonal cash use, primarily for annual compensation payments. The company stated its expectation to be cash-generative for the remainder of the year, with sequential improvement in each quarter. For investors, the coming quarters will be a test of this strategy, as they watch to see if the robust growth in glaucoma and continued cost discipline can successfully offset the persistent headwinds in the global market.